Buloxibutid

Vicore Pharma presented promising Phase 2a trial data at the 2025 ATS Conference showing buloxibutid significantly improved lung function in idiopathic pulmonary fibrosis patients compared to existing treatments.

The EMA's CHMP has recommended approval of Ofev (nintedanib) as the first treatment for systemic sclerosis-related interstitial lung disease in the EU, marking a significant advancement for this rare condition.

Refoxy Pharma secured $9.58 million to advance its FOXO3-targeting IPF drug, RP-01, aiming to modulate tissue repair mechanisms.

Vicore Pharma's buloxibutid demonstrated significant lung function improvement in IPF patients, with an average FVC increase of 216ml over 36 weeks compared to the typical 180ml decline in untreated patients.